AdaptDx Selected to be Part of the MACUSTAR Study
Professor Michael Larsen
Professor Michael Larsen from the University of Copenhagen explains the MACUSTAR project, a 5-year study aimed at exploring novel outcome measures for future interventional trials in patients with intermediate AMD. AdaptDx by MacuLogix has been selected as a functional testing device for candidate clinical endpoint development in the study.
MacuStar study on AMD is underway in Europe
There’s a very big Natural History study that has just begun here in Europe. It’s called MacuStar. It’s sponsored by the European Union and by the pharmaceutical industry and it will follow patients with different degrees of AMD. The main body of the study population consisting of people with intermediate AMD. We will follow them to measure rates of progression without any intervention just so that it will be known in the future, what is the rate by which people progress to higher levels of AMD? What is the rate at which their dark adaptation becomes increasingly deficient? For which subgroups that is more true than others. And this is an important information that we can get thanks to the MacuLogix instrument because it’s standardized, it’s easy to use, it’s fast, and convenient compared to the Goldmann-Weekers where it may take 20 to 40 minutes to find final threshold, which is relevant in some contexts but for what we’re doing here it looks like the standardized Rod Intercept or the rate of adaptation in the early phase of broad annotation is the relevant parameters. You have to realize that AMD is still a tremendous problem. As you get to the stage where we can do something about that, we need to intervene earlier with other drugs or we need to supplement the VEGF inhibitor treatment with a treatment that actually stops AMD and not just treats a complication.